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acterized by potential hemodynamic instability, potential coexisting renal
failure, and the need for a high volume of contrast medium. There were 354
consecutive patients undergoing primary angioplasty for myocardial infarc-
tion assigned to one of three groups. Group 1 consisted of 116 patients
assigned a standard dose of N-acetylcysteine (a 600-mg intravenous [IV]
bolus before angioplasty and an oral [po] dose of 600 mg twice daily [bid]
for 48 hours after angioplasty). Group 2 was 119 patients assigned to a
double dose of N-acetylcysteine (a 1200-mg IV bolus and 1200 mg po bid
for 48 hours after angioplasty). There were 119 patients assigned to a
placebo group.
Serum creatinine levels increased 25% or more after intervention in 33%
of the control patients (n  39), in 15% of the standard N-acetylcysteine
dosing group (n 17), and in 8% of the high N-acetylcysteine dosing group
(n  10; P  .001). Patients in whom contrast-medium-induced nephrop-
athy developed had higher in-hospital mortality (26% vs 1%, P  .001).
Rates of a composite end point of death, acute renal failure requiring
temporary renal replacement therapy, or need for mechanical ventilation
were 18% in the placebo group, 7% in the standard N-acetylcysteine group,
and 5% in the high dose N-acetylcysteine group (P  .002).
Comment: This is obviously a study of urgent angiography and angio-
plasty in patients with coronary artery disease. However, it is likely the results
of this study can be extrapolated to patients with peripheral vascular disease.
The importance of the report resides in the fact it may be possible to prevent
contrast nephropathy with N-acetylcysteine prophylaxis administered at the
time of the angiographic procedure rather than beginning in the days before
the procedure.
Effects of argatroban therapy, demographic variables, and platelet
count on thrombotic risk in heparin-induced thrombocytopenia
Lewis BE, Wallis DE, Hursting MJ, et al. Chest 2006;129:1407-16.
Conclusion: Argatroban provides excellent antithrombotic therapy in
patients with heparin-induced thrombocytopenia (HIT).
Summary: The authors evaluated thrombotic risk of HIT with respect
to the effects of argatroban, a direct thrombin inhibitor, patient demograph-
ics, and platelet count. This was a retrospective study designed to analyze
thrombotic outcomes in 882 patients with HIT, of whom 697 patients who
received argatroban at doses of 1.7 to 2.0 g/(kg · min) for 5 to 7 days.
These patients were compared with 185 historical control subjects from a
previously reported prospective study. The primary end point was a com-
posite time-to-event analysis that included death owing to thrombosis, a
new thrombosis 37 days, and amputation secondary to HIT-associated
thrombosis. Individual components of the primary end point were also
analyzed, and hazard ratios were estimated for treatment with and without
adjustments for baseline platelet count, race, weight, gender, and age.
Compared with control subjects, argatroban significantly reduced the
thrombotic composite end point (HIT: hazard ratio, 0.33; 95% confidence
interval, 0.20 to 0.54; P .001). For HIT with thrombosis, the hazard ratio
for treatment with argatroban was 0.39 (95% confidence interval, 0.25 to
0.62; P  .001). There was no influence of covariant adjustments. More
patients taking argatroban remained free of thrombotic events during
follow-up than did control subjects. This was independent of whether
baseline thrombosis was present or absent. Argatroban also significantly
reduced new thrombosis (P  .001) and death due to thrombosis (P 
.001). The control group and the argatroban-treated group had similar
major bleeding episodes (6% to 7%, P  .74). Nonwhite patients had a two
times greater risk of thrombotic events. Thrombotic risks were also increased
1.7 times in women vs men with HIT and thrombosis. Thrombotic events
were also increased with decreasing weight or decreasing platelet count.
Comment: This study confirms the effectiveness of argatroban in
treating HIT. Note that HIT patients with lower body weight and more
severe thrombocytopenia, as well as those who were nonwhite, had greater
HIT-associated thrombotic complications.
N-acetylcysteine for the prevention of kidney injury in abdominal
aortic surgery: A randomized, double-blind, placebo-controlled trial
Hynninen MS, Niemi TT, Poyhia R, et al. Anesth Analg 2006;102:1638-45.
Conclusion: N-acetylcysteine does not protect against renal injury
during elective aortic operation.
Summary: There are conflicting results about whether N-acetylcysteine
protects against contrast-induced nephropathy (N Engl J Med 2000; 43:
180-4 and Am J Kidney Disease 2004;43:1-9). In this study, the authors
sought to evaluate whether intravenous N-acetylcysteine can prevent renal
injury in patients undergoing abdominal aortic surgery. This was a prospec-
tive, randomized, placebo-controlled, double-blind trial. Patients without
known renal dysfunction were randomly allocated to receive either
N-acetylcysteine (150 mg/kg) during a 20-minute period, followed by an
infusion of 150 mg/kg in 250 mL of 5% dextrose during 24 hours, or
placebo. The drug infusion was started after induction of anesthesia. Renal
injury was the primary outcome measure as measured by increases in the
urinary N-acetyl--D-glucosaminidase (NAG)/creatinine ratio (indicator of
renal tubular injury) and the urinary albumin/creatinine ratio as an indicator
of glomerular injury. Serum cystatin C concentrations and plasma creatinine
were used to measure renal function.
Seventy patients were randomized: 34 receivedN-acetylcysteine and 35
received the placebo. One was withdrawn from the study when intra-
abdominal carcinomatosis precluded aortic reconstruction. There were 49
patients treated for aneurysm disease and 21 for occlusive disease. Only two
suprarenal aortic clamps were used, both in the placebo group. Aortic
cross-clamp times were a mean of 67 minutes (range, 22 to 159 minutes) in
the N-acetylcysteine group and 74 minutes (range, 22 to 156 minutes) in
the placebo group (P  .350). The differences in the two groups between
length of operation, intraoperative blood loss, and administration of intra-
venous fluids were not significant.
The urinary NAG/creatinine ratio increased from baseline to before
cross-clamp and remained increased on day 5 in both groups. The urinary
albumin/creatinine ratio also increased significantly from baseline to 6 hours
after declamping in the N-acetylcysteine group. There were no significant
changes in the NAG/creatinine ratio and the albumin/creatinine ratio
between the 2 groups. There were no changes in plasma creatinine and
serum cystatin C values between the 2 groups.
Comment: It is known that infrarenal and suprarenal aortic cross-
clamping can induce renal dysfunction. However, it would seem more likely
that suprarenal aortic clamping may produce changes in renal function of
greater magnitude than infrarenal aortic clamping. It would be interesting to
repeat this study in centers with a high volume of thoracoabdominal aneu-
rysm repair, and/or in centers in which there are relatively large numbers of
open abdominal aortic aneurysm repairs requiring suprarenal aortic clamps.
Cerebral emboli as a potential cause of Alzheimer’s disease and vascular
dementia: Case-control study
Purandare N, Burns A, Daly KJ, et al. BMJ 2006;332:1119-22.
Conclusion: Alzheimer’s disease and vascular dementia are associated
with spontaneous cerebral emboli.
Summary: Using a cross-sectional case–control study design, the
authors sought to compare the occurrence of spontaneous cerebral emboli
and venous-to-arterial circulation shunts in control patients without demen-
tia and in patients with vascular dementia or Alzheimer’s disease. There were
150 age-matched and sex-matched controls for the 170 patients with
dementia (85 with Alzheimer’s disease and 85 with vascular dementia).
Patients were excluded from the study if they were taking anticoagulant
therapy or had severe cognitive dysfunction or severe dementia. Spontane-
ous cerebral emboli were detected with transcranial Doppler monitoring of
the middle cerebral artery for 1 hour. Venous-to-arterial circulation shunts
were evaluated using transcranial Doppler in combination with intravenous
microbubbles as an ultrasound contrast agent.
Spontaneous cerebral emboli were detected in 40% of the patients with
Alzheimer’s disease (n  32) and in 37% of patients with vascular dementia
(n  31). In contrast, spontaneous cerebral emboli were detected in only
14% of control patients. Odds ratios adjusted for vascular risk factors for
spontaneous cerebral emboli were 2.70 (95% confidence interval, 1.18 to
6.21) for Alzheimer’s disease and 5.36 (95% confidence interval, 1.24 to
23.18) for vascular dementia. Carotid disease was no more frequent in the
dementia patients than the control patients. A venous-to-arterial shunt
indicative of a patent foramen ovale was found in 32% of Alzheimer’s disease
patients, in 29% of vascular dementia patients, and in about 21% of control
patients, giving nonsignificant odds ratios for arterial circulation shunts as a
contribution to Alzheimer’s disease or vascular dementia.
Comment: Spontaneous cerebral emboli can be detected in more than
half of patients with 70% carotid artery stenosis. This study suggests that
spontaneous cerebral emboli come from other sources in addition to carotid
artery disease and that these sources of cerebral emboli may contribute to the
development of Alzheimer’s disease or vascular dementia. It will be interest-
ing to see if long-term pharmacologic manipulation can someday reduce
spontaneous cerebral emboli in patients with Alzheimer’s disease or vascular
dementia as well as in patients with carotid stenosis.
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